Comparing Viridian Therapeutics (NASDAQ:VRDN) & Grail (NASDAQ:GRAL)

Viridian Therapeutics (NASDAQ:VRDN) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current recommendations for Viridian Therapeutics and Grail, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	3	9	0	2.75
Grail	0	3	0	0	2.00

Viridian Therapeutics presently has a consensus target price of $35.70, indicating a potential upside of 129.88%. Grail has a consensus target price of $16.00, indicating a potential downside of 63.53%. Given Viridian Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Grail.

Profitability

This table compares Viridian Therapeutics and Grail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%
Grail	N/A	N/A	N/A

Earnings & Valuation

This table compares Viridian Therapeutics and Grail”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$302,000.00	4,073.44	-$237.73 million	($4.31)	-3.60
Grail	$125.60 million	11.74	N/A	N/A	N/A

Grail has higher revenue and earnings than Viridian Therapeutics.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About Grail

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.